Risk-stratified multi-round PSA screening for prostate cancer integrating the screening reference level and subgroup-specific progression indicators

BACKGROUND: Although prostate-specific antigen (PSA) is widely used in prostate cancer (PCa) screening, nearly half of PCa cases are missed and less than one-third of cases are non-lethal. Adopting diagnostic criteria in population-based screening and ignoring PSA progression are presumed leading ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiaomin, Zhang, Yu, Duan, Hongyuan, Yang, Lei, Sheng, Chao, Fan, Zeyu, Liu, Ya, Gao, Ying, Wang, Xing, Zhang, Qing, Lyu, Zhangyan, Song, Fangfang, Song, Fengju, Huang, Yubei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369696/
https://www.ncbi.nlm.nih.gov/pubmed/37496058
http://dx.doi.org/10.1186/s40001-023-01228-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369696/
https://www.ncbi.nlm.nih.gov/pubmed/37496058
http://dx.doi.org/10.1186/s40001-023-01228-x

Ejemplares similares